Dose-Escalation Study of Azacitidine Followed By High-Dose Cytarabine (HiDAC) and Mitoxantrone (Mito) for Remission Induction in High-Risk Acute Myeloid Leukemia (AML)

被引：2

作者：

Karimi, Yasmin H. ^{[1
]}

Jain, Nitin ^{[2
]}

Green, Margaret ^{[1
]}

Godley, Lucy A. ^{[1
]}

Weiner, Howie Lawrence ^{[1
]}

Malnassy, Gregory ^{[1
]}

Fulton, Noreen ^{[1
]}

Artz, Andrew ^{[1
]}

Liu, Hongtao ^{[1
]}

Thirman, Michael J. ^{[1
]}

Daunov, Michael ^{[1
]}

Larson, Richard A. ^{[1
]}

Stock, Wendy ^{[1
]}

Odenike, Olatoyosi ^{[1
]}

机构：

[1] Univ Chicago, Med Ctr, Chicago, IL 60637 USA

[2] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

来源：

BLOOD | 2015年 / 126卷 / 23期

关键词：

D O I：

10.1182/blood.V126.23.118.118

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3

共 50 条

[21] Intensive timed sequential remission induction chemotherapy with high-dose cytarabine for childhood acute myeloid leukemia
Loeb, DM
Bowers, DC
Civin, CI
Friedman, AD
MEDICAL AND PEDIATRIC ONCOLOGY, 2001, 37 (04): : 365 - 371
[22] Influence of BMI on outcomes of high-dose cytarabine and mitoxantrone induction therapy for AML
Burhani, Mansoor
Dave, Manish J.
Venugopal, Parameswaran
Larson, Melissa L.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[23] High-dose mercaptopurine and intermediate-dose cytarabine during first remission of acute myeloid leukemia
Canpolat, C
Jeha, S
Lockhart, S
Ramirez, I
Zipf, T
Pinkel, D
CANCER INVESTIGATION, 1997, 15 (02) : 121 - 126
[24] High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemia
Schlenk, RF
Germing, U
Hartmann, F
Glasmacher, A
Fischer, JT
Fuentes, FDY
Götze, K
Pralle, H
Nerl, C
Salwender, H
Grimminger, W
Petzer, A
Hensel, M
Benner, A
Zick, L
Döhner, K
Fröhling, S
Döhner, H
LEUKEMIA, 2005, 19 (06) : 978 - 983
[25] High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemia
R F Schlenk
U Germing
F Hartmann
A Glasmacher
J T Fischer
F del Valle y Fuentes
K Götze
H Pralle
C Nerl
H Salwender
W Grimminger
A Petzer
M Hensel
A Benner
L Zick
K Döhner
S Fröhling
H Döhner
Leukemia, 2005, 19 : 978 - 983
[26] IDARUBICIN, HIGH-DOSE CYTARABINE AND ETOPOSIDE FOR REMISSION INDUCTION IN THERAPY-RELATED ACUTE MYELOID-LEUKEMIA
PHILPOTT, N
MEHTA, J
TRELEAVEN, J
POWLES, R
LEUKEMIA & LYMPHOMA, 1994, 15 (1-2) : 127 - 130
[27] Timed sequential therapy with high-dose cytarabine and mitoxantrone as an effective and safe induction regimen for acute myeloid leukemia.
Larson, Melissa L.
Burhani, Sakina
Gallas, Kirstin
Katz, Deborah Ann
Hoyt, Maura
Venugopal, Parameswaran
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[28] Idarubicin, high-dose cytarabine and etoposide for remission induction in patients with relapsed acute leukemia
Mehta, J
Powles, R
Singhal, S
Horton, C
Prediville, J
Glynne, P
Zomas, A
Hamblin, S
Saso, R
Mackay, H
Treleaven, J
BLOOD, 1995, 86 (10) : 2041 - 2041
[29] Phase II Study of High Dose Cytarabine Followed By Pembrolizumab in Relapsed/Refractory Acute Myeloid Leukemia (AML)
Zeidner, Joshua F.
Vincent, Benjamin G.
Ivanova, Anastasia
Foster, Matthew
Coombs, Catherine C.
Jamieson, Katarzyna
Van Deventer, Hendrik
Scibilia, Richard
Blanchard, Laura
Frank, Cassiopeia
Gallagher, Sean
Matson, Melissa
Pepin, Katherine
Vaught, Lori
Vogler, Nancy
Gojo, Ivana
Luznik, Leo
Serody, Jonathan S.
BLOOD, 2017, 130
[30] Treatment of core binding factor (CBF) acute myeloid leukemia (AML) with post-remission high-dose cytarabine (HiDAC): Results from CALGB 9621.
Kolitz, JE
George, SL
Barrier, R
Hoke, E
Hurd, DD
Velez-Garcia, E
Powell, BL
Marcucci, G
Baer, MR
Hohl, RJ
Mrozek, K
Carroll, AJ
Edwards, CG
Caligiuri, MA
Vardiman, JW
Bloomfield, C
Larson, RA
BLOOD, 2003, 102 (11) : 176A - 176A

← 1 2 3 4 5 →